On BMS’ Plea, Delhi Court Nixes Hetero’s Dasatinib Application; Directs India’s Drug Controller To Examine Patent Violations
This article was originally published in PharmAsia News
Executive SummaryMUMBAI - In a decision that could have a far-reaching impact on drug patent cases in India, the Delhi High Court has directed the Drug Controller General of India to monitor for patent infringements by any party while a drug's approval application is scrutinized
You may also be interested in...
Natco has gained approval from a state-level agency rather than India’s DCGI, opening up a new front in the battle between Indian companies and MNCs.